Literature DB >> 18626304

Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients.

Manuel Ramos-Casals1, Roser Solans, Jose Rosas, María Teresa Camps, Antonio Gil, Javier Del Pino-Montes, Jaime Calvo-Alen, Juan Jiménez-Alonso, Maria-Luisa Micó, Juan Beltrán, Rafael Belenguer, Lucio Pallarés.   

Abstract

We conducted the current study to characterize the clinical presentation of primary Sjögren syndrome (SS) in a large cohort of Spanish patients and to determine whether epidemiologic, clinical, and analytical features modulate disease expression. Patients were from the GEMESS Study group, which was formed in 2005 and included 12 Spanish reference centers. By March 2007, the database included 1010 consecutive patients, recruited since 1994, both incident and prevalent cases. The cohort included 937 women and 73 men (ratio, 13:1), with a mean age of 53 years at diagnosis and 59 years at inclusion in the registry. Multivariate analysis showed that male patients had a lower frequency of thyroiditis, Raynaud phenomenon, and antinuclear antibodies. Young-onset patients had a low degree of sicca involvement (xerostomia and parotid enlargement) and a high frequency of immunologic markers (anti-Ro/SS-A and low C4 levels). Patients with disease duration of more than 10 years had a higher prevalence of xerophthalmia, parotid enlargement, lung involvement, and peripheral neuropathy in comparison with incident cases. The subset of patients with anti-Ro/La antibodies had the highest prevalence of most systemic, hematologic, and immunologic alterations (higher frequency of Raynaud phenomenon, altered parotid scintigraphy, positive salivary gland biopsy, peripheral neuropathy, thrombocytopenia, and rheumatoid factor). Hypocomplementemia was associated with a higher frequency of vasculitis and lymphoma, and cryoglobulins with a higher frequency of parotid enlargement, vasculitis, and leukopenia.Epidemiologic, clinical, and analytical features have a significant impact on the clinical presentation of primary SS, influencing the results of the main diagnostic tests, the prevalence and diversity of extraglandular involvement, and the frequency of the main immunologic markers. Primary SS should be considered as a systemic autoimmune disease that can express in many guises beyond sicca involvement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18626304     DOI: 10.1097/MD.0b013e318181e6af

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  119 in total

Review 1.  Autoantibodies in Sjögren's Syndrome.

Authors:  Anum Fayyaz; Biji T Kurien; R Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2016-06-21       Impact factor: 2.670

2.  Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.

Authors:  Barbara M Segal; Abu N M Nazmul-Hossain; Ketan Patel; Pamela Hughes; Kathy L Moser; Nelson L Rhodus
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2011-04-16

Review 3.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

4.  Primary Sjögren's syndrome and risk of ischemic stroke: a nationwide study.

Authors:  Chia-Hung Chiang; Chia-Jen Liu; Ping-Jen Chen; Chin-Chou Huang; Chien-Yi Hsu; Wan-Leong Chan; Po-Hsun Huang; Tzeng-Ji Chen; Shing-Jong Lin; Jaw-Wen Chen; Hsin-Bang Leu
Journal:  Clin Rheumatol       Date:  2014-03-21       Impact factor: 2.980

5.  Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases.

Authors:  Wei Zhang; Fan Wang; Hong Wang; Bingzhu Hua; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2018-10-02       Impact factor: 2.980

6.  [Sjögren's syndrome].

Authors:  T Witte
Journal:  Z Rheumatol       Date:  2014-02       Impact factor: 1.372

Review 7.  [Pathogenesis and diagnosis of Sjögren's syndrome].

Authors:  T Witte
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

8.  Prognostic value of Sjögren's syndrome autoantibodies.

Authors:  R Hal Scofield; Anum Fayyaz; Biji T Kurien; Kristi A Koelsch
Journal:  J Lab Precis Med       Date:  2018-10-30

9.  Serum CXCL4 increase in primary Sjögren's syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement.

Authors:  Serena Vettori; Rosaria Irace; Antonella Riccardi; Daniela Iacono; Luciana Pellecchia; Lucia Vicedomini; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2016-08-26       Impact factor: 2.980

10.  Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; César Jiménez-Hernández; Mario Jiménez-Hernández; Arnulfo Nava-Zavala; Carlos Riebeling
Journal:  Int J Clin Rheumtol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.